Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update-Reference-Cited by-同舟云学术

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update

Published:2017-10-18 Issue:3 Volume:33 Page:457-461
ISSN:0931-041X
Container-title:Pediatric Nephrology
language:en
Short-container-title:Pediatr Nephrol

Author:

Ardissino Gianluigi,Tel Francesca,Sgarbanti Martina,Cresseri Donata,Giussani Antenore,Griffini Samantha,Grovetto Elena,Possenti Ilaria,Perrone Michela,Testa Sara,Paglialonga Fabio,Messa Piergiorgio,Cugno Massimo

Publisher

Springer Science and Business Media LLC

Subject

Nephrology,Pediatrics, Perinatology and Child Health

Link

http://link.springer.com/article/10.1007/s00467-017-3813-2/fulltext.html

Reference9 articles.

1. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181

2. Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701–711

3. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 91:539–551

4. Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G (2014) Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 12:1440–1448

5. Cugno M, Tedeschi S, Ardissino G (2015) Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment. J Thromb Haemost 13:485–486

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement-Mediated Thrombotic Microangiopathy after Kidney Transplant: Should Treatment with C5 Inhibitor Be Lifelong?;Nephron;2024-04-18

2. Complement Blockade, a New Therapeutic Approach in Malignant Hypertension;Internal Medicine;2024-03-01

3. A Differential Diagnosis of Thrombotic Microangiopathy in a 7-Year-Old Girl;Clinical Chemistry;2024-02

4. The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series;Therapeutic Advances in Neurological Disorders;2024-01

5. Complement Blockade, a New Therapeutic Approach in Malignant Hypertension;Internal Medicine;2023-12-01